These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

300 related articles for article (PubMed ID: 34537926)

  • 1. Roxadustat for the Maintenance Treatment of Anemia in Patients with End-Stage Kidney Disease on Stable Dialysis: A European Phase 3, Randomized, Open-Label, Active-Controlled Study (PYRENEES).
    Csiky B; Schömig M; Esposito C; Barratt J; Reusch M; Valluri U; Sulowicz W
    Adv Ther; 2021 Oct; 38(10):5361-5380. PubMed ID: 34537926
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and Cardiovascular Safety of Roxadustat in Dialysis-Dependent Chronic Kidney Disease: Pooled Analysis of Four Phase 3 Studies.
    Barratt J; Sulowicz W; Schömig M; Esposito C; Reusch M; Young J; Csiky B
    Adv Ther; 2021 Oct; 38(10):5345-5360. PubMed ID: 34523074
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oral roxadustat three times weekly in ESA-naïve and ESA-converted patients with anemia of chronic kidney disease on hemodialysis: Results from two phase 3 studies.
    Akizawa T; Ueno M; Shiga T; Reusch M
    Ther Apher Dial; 2020 Dec; 24(6):628-641. PubMed ID: 31891449
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intermittent Oral Dosing of Roxadustat in Peritoneal Dialysis Chronic Kidney Disease Patients with Anemia: A Randomized, Phase 3, Multicenter, Open-Label Study.
    Akizawa T; Otsuka T; Reusch M; Ueno M
    Ther Apher Dial; 2020 Apr; 24(2):115-125. PubMed ID: 31222951
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Phase 3, Multicenter, Randomized, Two-Arm, Open-Label Study of Intermittent Oral Dosing of Roxadustat for the Treatment of Anemia in Japanese Erythropoiesis-Stimulating Agent-Naïve Chronic Kidney Disease Patients Not on Dialysis.
    Akizawa T; Yamaguchi Y; Otsuka T; Reusch M
    Nephron; 2020; 144(8):372-382. PubMed ID: 32580188
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase 3, Randomized, Double-Blind, Active-Comparator (Darbepoetin Alfa) Study of Oral Roxadustat in CKD Patients with Anemia on Hemodialysis in Japan.
    Akizawa T; Iwasaki M; Yamaguchi Y; Majikawa Y; Reusch M
    J Am Soc Nephrol; 2020 Jul; 31(7):1628-1639. PubMed ID: 32493693
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Roxadustat (FG-4592) Versus Epoetin Alfa for Anemia in Patients Receiving Maintenance Hemodialysis: A Phase 2, Randomized, 6- to 19-Week, Open-Label, Active-Comparator, Dose-Ranging, Safety and Exploratory Efficacy Study.
    Provenzano R; Besarab A; Wright S; Dua S; Zeig S; Nguyen P; Poole L; Saikali KG; Saha G; Hemmerich S; Szczech L; Yu KH; Neff TB
    Am J Kidney Dis; 2016 Jun; 67(6):912-24. PubMed ID: 26846333
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase 3b, multicenter, open-label, single-arm study of roxadustat within a US dialysis organization: The DENALI study.
    Larkin J; Hymes J; Britton ML; Oluwatosin Y; Nolen J; Zhu L; Silva A
    Hemodial Int; 2024 Jan; 28(1):59-71. PubMed ID: 37875459
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Roxadustat for the treatment of anaemia in chronic kidney disease patients not on dialysis: a Phase 3, randomized, open-label, active-controlled study (DOLOMITES).
    Barratt J; Andric B; Tataradze A; Schömig M; Reusch M; Valluri U; Mariat C
    Nephrol Dial Transplant; 2021 Aug; 36(9):1616-1628. PubMed ID: 34077510
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Roxadustat Treatment for Anemia in Patients Undergoing Long-Term Dialysis.
    Chen N; Hao C; Liu BC; Lin H; Wang C; Xing C; Liang X; Jiang G; Liu Z; Li X; Zuo L; Luo L; Wang J; Zhao MH; Liu Z; Cai GY; Hao L; Leong R; Wang C; Liu C; Neff T; Szczech L; Yu KP
    N Engl J Med; 2019 Sep; 381(11):1011-1022. PubMed ID: 31340116
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Roxadustat Versus Epoetin Alfa for Treating Anemia in Patients with Chronic Kidney Disease on Dialysis: Results from the Randomized Phase 3 ROCKIES Study.
    Fishbane S; Pollock CA; El-Shahawy M; Escudero ET; Rastogi A; Van BP; Frison L; Houser M; Pola M; Little DJ; Guzman N; Pergola PE
    J Am Soc Nephrol; 2022 Apr; 33(4):850-866. PubMed ID: 35361724
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Roxadustat for anemia in patients with end-stage renal disease incident to dialysis.
    Provenzano R; Shutov E; Eremeeva L; Korneyeva S; Poole L; Saha G; Bradley C; Eyassu M; Besarab A; Leong R; Liu CS; Neff TB; Szczech L; Yu KP
    Nephrol Dial Transplant; 2021 Aug; 36(9):1717-1730. PubMed ID: 33629100
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Factors affecting the doses of roxadustat vs darbepoetin alfa for anemia treatment in hemodialysis patients.
    Akizawa T; Yamaguchi Y; Majikawa Y; Reusch M
    Ther Apher Dial; 2021 Oct; 25(5):575-585. PubMed ID: 33200512
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety of Roxadustat Versus Erythropoiesis-Stimulating Agents in Patients with Anemia of Non-dialysis-Dependent or Incident-to-Dialysis Chronic Kidney Disease: Pooled Analysis of Four Phase 3 Studies.
    Barratt J; Dellanna F; Portoles J; Choukroun G; De Nicola L; Young J; Dimković N; Reusch M
    Adv Ther; 2023 Apr; 40(4):1546-1559. PubMed ID: 36749544
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Factors Affecting Doses of Roxadustat Versus Darbepoetin Alfa for Anemia in Nondialysis Patients.
    Akizawa T; Tanaka-Amino K; Otsuka T; Yamaguchi Y
    Am J Nephrol; 2021; 52(9):702-713. PubMed ID: 34628408
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Roxadustat for Treating Anemia in Patients with CKD Not on Dialysis: Results from a Randomized Phase 3 Study.
    Fishbane S; El-Shahawy MA; Pecoits-Filho R; Van BP; Houser MT; Frison L; Little DJ; Guzman NJ; Pergola PE
    J Am Soc Nephrol; 2021 Mar; 32(3):737-755. PubMed ID: 33568383
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molidustat for Renal Anemia in Nondialysis Patients Previously Treated with Erythropoiesis-Stimulating Agents: A Randomized, Open-Label, Phase 3 Study.
    Yamamoto H; Nobori K; Matsuda Y; Hayashi Y; Hayasaki T; Akizawa T
    Am J Nephrol; 2021; 52(10-11):884-893. PubMed ID: 34569482
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase 3b, multicenter, open-label, single-arm study of roxadustat (ASPEN): Operational learnings within United States dialysis organizations.
    Fishbane S; Vishnepolsky M; Oluwatosin Y; Nolen J; Zhu L; Cooper K; Young A
    Hemodial Int; 2023 Oct; 27(4):400-410. PubMed ID: 37380364
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and Safety of Daprodustat for Treatment of Anemia of Chronic Kidney Disease in Incident Dialysis Patients: A Randomized Clinical Trial.
    Singh AK; Cizman B; Carroll K; McMurray JJV; Perkovic V; Jha V; Johansen KL; Lopes RD; Macdougall IC; Obrador GT; Waikar SS; Wanner C; Wheeler DC; Wiecek A; Stankus N; Strutz F; Blackorby A; Cobitz AR; Meadowcroft AM; Paul G; Ranganathan P; Sedani S; Solomon S
    JAMA Intern Med; 2022 Jun; 182(6):592-602. PubMed ID: 35377393
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Roxadustat for the treatment of anemia in chronic kidney disease patients not on dialysis: a Phase 3, randomized, double-blind, placebo-controlled study (ALPS).
    Shutov E; Sułowicz W; Esposito C; Tataradze A; Andric B; Reusch M; Valluri U; Dimkovic N
    Nephrol Dial Transplant; 2021 Aug; 36(9):1629-1639. PubMed ID: 33630072
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.